- Home
- PAXS vs ARVN Comparison
PAXS vs ARVN Comparison
Compare PAXS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAXS | ARVN |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 721.4M | 781.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PAXS | ARVN |
|---|---|---|
| Price | $15.57 | $13.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $15.57 |
| AVG Volume (30 Days) | 162.4K | ★ 722.7K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.63 | $5.90 |
| 52 Week High | $16.56 | $18.93 |
Technical Indicators
Market Signals| Indicator | PAXS | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 60.75 |
| Support Level | $15.35 | $11.07 |
| Resistance Level | $15.64 | $13.97 |
| Average True Range (ATR) | 0.22 | 0.81 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 37.68 | 97.13 |
Price Performance
Historical ComparisonAbout PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.